Oncolytics Biotech (ONCY)
(Delayed Data from NSDQ)
$1.02 USD
-0.01 (-0.97%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.02 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ONCY 1.02 -0.01(-0.97%)
Will ONCY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ONCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ONCY
Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
ONCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
Novartis (NVS) to Report Q1 Earnings: What to Expect?
After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY)
Other News for ONCY
Oncolytics Biotech Highlights at Growth Conference
Oncolytics Biotech? to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference
Buy Rating on Oncolytics Biotech Backed by Strong Clinical Trials and Strategic Partnerships
Oncolytics Biotech Announces Equity Distribution Deal
Oncolytics Biotech Inc (ONCY) Q2 2024 Earnings Call Transcript Highlights: Financial Stability ...